| [1] |
Adler AI,Stevens RJ,Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)[J]. Kidney Int, 2003, 63(1): 225-232.
|
| [2] |
Heerspink HJ,Ninomiya T,Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials[J]. Lancet, 2009, 373(9668): 1009-1015.
|
| [3] |
Mancia G,Fagard R,Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. J Hypertens, 2013, 31(7): 1281-1357.
|
| [4] |
James PA,Oparil S,Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA, 2014, 311(5): 507-520.
|
| [5] |
KDIGO Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease[J]. Kidney Int Suppl, 2012, 2(5): 337-414.
|
| [6] |
American Diabetes Association. Standards of medical care in diabetes-2013[J]. diabetes Care, 2013, 36(Suppl 1): S11-S66.
|
| [7] |
American Diabetes Association. Standards of medical care in diabetes-2016 abridged for primary care providers[J]. Clin Diabetes, 2016, 34(1): 3-21.
|
| [8] |
American Diabetes Association. Standards of medical care in diabetes-2015[J]. Diabetes Care, 2015, 38(Suppl 1): S1-S174.
|
| [9] |
Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease[J]. Am J Kidney Dis, 2004, 43(5 Suppl 1): S1-S290.
|
| [10] |
Hsu TW,Liu JS,Hung SC, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia[J]. JAMA Intern Med, 2014, 174(3): 347-354.
|
| [11] |
Law MR,Morris JK,Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J]. BMJ, 2009, 338: b1665.
|
| [12] |
Palmer SC,Mavridis D,Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis[J]. Lancet, 2015, 385(9982): 2047-2056.
|
| [13] |
Bakris GL,Agarwal R,Chan JC. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial[J]. JAMA, 2015, 314(9): 884-894.
|
| [14] |
Dussol B,Moussi-Frances J,Morange S, et al. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease[J]. J Clin Hypertens (Greenwich), 2012, 14(1): 32-37.
|
| [15] |
James PA,Oparil S,Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA, 2014, 311(5): 507-520.
|
| [16] |
Dahlöf B,Devereux RB,Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol[J]. Lancet, 2002, 359(9311): 995-1003.
|
| [17] |
Badve SV,Roberts MA,Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis[J]. J Am Coll Cardiol, 2011, 58(11): 1152-1161.
|
| [18] |
Solini A,Zoppini G,Orsi E, et al. Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications[J]. J Hypertens, 2014, 32(12): 2401-2410.
|
| [19] |
De Nicola L,Gabbai FB,Agarwal R, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients[J]. J Am Coll Cardiol, 2013, 61(24): 2461-2467.
|